Posted by Michael Wonder on 15 Mar 2023
Zanubrutinib in chronic lymphocytic leukaemia: additional benefit for certain patients
15 March 2023 - For adults with relapsed/refractory chronic lymphocytic leukaemia who have not yet received a BTK or BCL2 inhibitor, zanubrutinib has a significant or minor additional clinical benefit over ibrutinib, depending on age.
Zanubrutinib, a second generation Bruton's tyrosine kinase inhibitor, has been approved for multiple indications. The IQWiG has investigated its use in adults with chronic lymphocytic leukaemia after a recurrence or in the case of a refractory disease, i.e. one that has not responded to previous treatment, when compared to the appropriate comparator therapy.
